Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARLOS E ARCE-LARA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1326265273
CMS profile
1254977
Location
CASA GRANDE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,721.45

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,463.32 144
Consulting Fee $822.50 1
Education $268.97 4
Long term medical supply or device loan $166.66 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $891.38 4
NOVARTIS PHARMACEUTICALS CORPORATION $397.81 13
AstraZeneca Pharmaceuticals LP $287.42 10
Incyte Corporation $220.85 6
Genentech USA, Inc. $201.67 9
EMD Serono, Inc. $181.05 5
Celgene Corporation $173.92 13
GENZYME CORPORATION $167.66 4
Lilly USA, LLC $159.89 3
Astellas Pharma US Inc $155.99 5
Merck Sharp & Dohme LLC $137.80 7
Karyopharm Therapeutics Inc. $134.16 3
PFIZER INC. $104.88 6
Janssen Biotech, Inc. $104.86 2
Pharmacyclics LLC, An AbbVie Company $101.52 4
AVEO Pharmaceuticals, Inc. $101.07 3
Takeda Pharmaceuticals U.S.A., Inc. $94.26 4
Gilead Sciences, Inc. $82.99 4
Amgen Inc. $73.69 4
INTUITIVE SURGICAL, INC. $73.30 1
Puma Biotechnology, Inc. $71.15 3
E.R. Squibb & Sons, L.L.C. $70.78 4
AbbVie Inc. $60.83 2
Seagen Inc. $53.86 3
Regeneron Healthcare Solutions, Inc. $43.86 2
ARRAY BIOPHARMA INC $41.98 2
GlaxoSmithKline, LLC. $40.81 3
Davol Inc. $37.87 1
Mirati Therapeutics, Inc. $37.68 2
Fennec Pharmaceuticals, Inc. $37.24 1
Eisai Inc. $36.38 2
Stemline Therapeutics Inc. $35.30 1
TerSera Therapeutics LLC $30.58 1
Kite Pharma, Inc. $26.97 2
TAIHO ONCOLOGY, INC. $26.55 1
SOBI, INC $25.42 1
Adaptive Biotechnologies Corporation $23.60 1
Rigel Pharmaceuticals, Inc. $23.45 1
Pharmacosmos Therapeutics Inc. $22.40 1
Genmab U.S., Inc. $22.34 1
BeiGene USA, Inc. $22.29 1
Coherus Biosciences Inc. $19.79 1
MorphoSys, US Inc. $19.64 1
SERVIER PHARMACEUTICALS LLC $16.00 1
Alexion Pharmaceuticals, Inc. $15.75 1
Sun Pharmaceutical Industries Inc. $12.76 1

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARLOS E ARCE-LARA

NPI 1326265273 · CMS profile ID 1254977

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CASA GRANDE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326265273?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARLOS E ARCE-LARA, NPI 1326265273, CMS profile ID 1254977. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326265273?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CARLOS E ARCE-LARA, NPI 1326265273, CMS profile ID 1254977. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326265273?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CARLOS E ARCE-LARA, NPI 1326265273, CMS profile ID 1254977, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1326265273?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $4,721.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $15.3208/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012010759 CMS
Novartis Pharmaceuticals Corporation $33.2908/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991642197 CMS
Incyte Corporation $14.9608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044570759 CMS
AstraZeneca Pharmaceuticals LP $102.4808/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014755785 CMS
Genentech USA, Inc. $21.9708/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040321619 CMS
Genentech USA, Inc. $19.1508/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040321575 CMS
TAIHO ONCOLOGY, INC. $26.5508/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055231769 CMS
AbbVie Inc. $28.9708/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996159499 CMS
GENZYME CORPORATION $19.0808/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049932737 CMS
Astellas Pharma US Inc $13.3508/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034382721 CMS
PFIZER INC. $9.6608/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049350655 CMS
Pharmacyclics LLC, An AbbVie Company $23.2508/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998281263 CMS
EMD Serono, Inc. $12.0108/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032315203 CMS
Lilly USA, LLC $121.8208/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031312191 CMS
Lilly USA, LLC $17.6407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031306321 CMS
Merck Sharp & Dohme LLC $15.8307/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048271693 CMS
Novartis Pharmaceuticals Corporation $26.6507/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991642179 CMS
Genentech USA, Inc. $24.0007/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040321571 CMS
Novartis Pharmaceuticals Corporation $16.0607/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991642191 CMS
Janssen Biotech, Inc. $82.9907/17/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988016811 CMS
Genentech USA, Inc. $28.5507/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040321601 CMS
Mirati Therapeutics, Inc. $16.6807/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057985533 CMS
Puma Biotechnology, Inc. $21.2707/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059059077 CMS
Celgene Corporation $15.6507/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017949 CMS
PFIZER INC. $17.3606/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050601211 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.9006/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055336031 CMS
Merck Sharp & Dohme LLC $24.3306/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048719081 CMS
Celgene Corporation $5.1206/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017945 CMS
AstraZeneca Pharmaceuticals LP $21.6006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016085343 CMS
Seagen Inc. $14.7606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995787515 CMS
Genentech USA, Inc. $29.0106/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040321615 CMS
Stemline Therapeutics Inc. $35.3006/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040022745 CMS
Gilead Sciences, Inc. $19.8906/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025820521 CMS
Kite Pharma, Inc. $13.7505/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025267019 CMS
Genmab U.S., Inc. $22.3405/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051343151 CMS
Regeneron Healthcare Solutions, Inc. $17.4405/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999079193 CMS
Celgene Corporation $12.7705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017919 CMS
Celgene Corporation $4.4405/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017925 CMS
Daiichi Sankyo Inc. $24.2205/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006412833 CMS
Genentech USA, Inc. $22.9105/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040321595 CMS
Merck Sharp & Dohme LLC $28.5605/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048271665 CMS
E.R. Squibb & Sons, L.L.C. $14.3005/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017857 CMS
PFIZER INC. $8.4705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050408535 CMS
AstraZeneca Pharmaceuticals LP $13.7805/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016016083 CMS
Celgene Corporation $28.8805/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017863 CMS
Astellas Pharma US Inc $13.0904/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034081473 CMS
Incyte Corporation $20.1304/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044570419 CMS
Incyte Corporation $20.5104/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044570432 CMS
Pharmacosmos Therapeutics Inc. $22.4004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046240795 CMS
Novartis Pharmaceuticals Corporation $15.6104/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991642155 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,647.37 67
PY2020 $320.19 16
PY2021 $1,010.55 31
PY2022 $3,807.33 164
PY2023 $4,721.45 151
PY2024 $1,660.42 23
PY2025 $5,615.10 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $18,340.00 26
PY2024 Principal investigator $14,353.00 16
PY2023 Principal investigator $1,994.95 1
PY2021 Principal investigator $2,935.93 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 11/03/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237261
Principal investigator 1 Janssen Research & Development, LLC $473.00 05/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237027
Principal investigator 1 Janssen Research & Development, LLC $473.00 05/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237224
Principal investigator 1 Janssen Research & Development, LLC $976.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175236877
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175236915
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175236947
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175236988
Principal investigator 1 Janssen Research & Development, LLC $976.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237006
Principal investigator 1 Janssen Research & Development, LLC $976.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237033
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237069
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237084
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237092
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237110
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237183
Principal investigator 1 Janssen Research & Development, LLC $976.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237243
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237292
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237300
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237307
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/28/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237404
Principal investigator 1 Janssen Research & Development, LLC $473.00 01/30/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175236964
Principal investigator 1 Janssen Research & Development, LLC $473.00 01/30/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237044
Principal investigator 1 Janssen Research & Development, LLC $473.00 01/30/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237192
Principal investigator 1 Janssen Research & Development, LLC $976.00 01/30/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237275
Principal investigator 1 Janssen Research & Development, LLC $473.00 01/30/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237336
Principal investigator 1 Janssen Research & Development, LLC $473.00 01/30/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237341
Principal investigator 1 Janssen Research & Development, LLC $473.00 01/30/2025 Non-covered Recipient Entity
Amercn Oncology Partners P A
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) No dispute reported 06/30/2026 1175237357